About this trial
This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years or older
planned for catheter ablation due to symptomatic paroxysmal atrial fibrillation
failure of at least one anti-arrhythmic drug
others
Disqualifiers
overall good health as established by multiple criteria
Trial design
Single group
Treatments tested in this trial
HeartLight
DeviceHeartLight Endoscopic Ablation System
Ablation
Procedure/SurgeryPulmonary vein isolation ablation
Treatment groups
Trial outcomes
Primary outcomes
The proportion of participants free from symptomatic atrial fibrillation (AF) or symptomatic atypical atrial flutter/atrial tachycardia (AFL/AT) lasting longer than 30 seconds post the 90 day blanking period
The outcome will be assessed from 91 days post procedure through 12 months
Other outcomes
Chronic Effectiveness
Freedom from symptomatic AF or symptomatic atypical AFL/AT
Chronic Safety
Reporting of adverse events
Effect of Operator Experience on primary effectiveness endpoint
Assess relationship between operator experience and freedom from symptomatic AF or symptomatic atypical AFL/AT
Effect of Operator Experience on primary safety endpoint
Assess relationship between operator experience and rate of Primary Adverse Events (PAE)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.